New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Says positive momentum continues to build, off to a strong start for the year. Says well positioned for sustained performance. Says global demand for Advate remains very strong. Says demand for Feiba remains robust. Says to date, has not experienced any new competition for cyclophosphamide. Says wide guidance range contemplates potential headwinds related to cyclophosphamide competition, foreign currency. Says guidance currently assumes FY cyclo benefit 20c per share. Sees FY interest expense $160M. Sees FY tax rate 21.5%. Says U.S. growth may moderate, but sees international growth accelerating on sequential basis in Q3, Q4. Sees FY CapEx approx. $1.8B. Sees FY Medical Products sales up 1%-2% excluding GAMBRO. Sees competition for cyclo later this year. Sees Specialty Pharmaceuticals sales growth in the 3%-5% range. Sees BioTherapeutics sales up 4%, BioSurgery/Vaccines sales growth in the low single digits. Comments made on the Q2 earnings conference call.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:02 EDTBAXBaxter presents IGSC 20% Phase 2,3 study
Subscribe for More Information
October 27, 2014
07:23 EDTBAXAmerican College of Surgeons holds a conference
Subscribe for More Information
07:22 EDTBAXAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
09:02 EDTBAXBaxter says FDA approves Obizur for acquired hemophilia A
Subscribe for More Information
October 21, 2014
06:29 EDTBAXBaxter management to meet with Leerink
Subscribe for More Information
October 20, 2014
09:04 EDTBAXBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use